Global colorectal cancer diagnostics and therapeutics market to grow at ~9% CAGR, reaching $73B by 2034

The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising colorectal cancer prevalence, increased awareness and early screening efforts, and advances in precision medicine including non-invasive diagnostics and targeted therapies. North America currently leads the market, supported by advanced healthcare infrastructure and strong pharmaceutical presence, while Asia-Pacific is the fastest-growing region due to expanding healthcare investments and rising disease incidence. Ongoing innovations such as AI-assisted diagnostics and immunotherapy approvals are expected to further enhance market expansion and improve patient outcomes globally.